RT Journal Article SR Electronic T1 Significant rise of Chlamydia pneumoniae diagnoses at Marseille University Hospitals, 2024, France JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2024.12.11.24318723 DO 10.1101/2024.12.11.24318723 A1 Edouard, Sophie A1 Attamna, Rayane A1 Million, Matthieu A1 Boschi, Céline A1 Delerce, Jeremy A1 Caputo, Aurélia A1 Stoupan, Didier A1 Diene, Seydina A1 Kacel, Idir A1 Andrieu, Claudia A1 Levasseur, Anthony A1 Chaudet, Hervé A1 Rolain, Jean-Marc A1 Lesage, Lucile A1 Morand, Aurélie A1 Fournier, Pierre-Edouard A1 Lagier, Jean-Christophe A1 Fenollar, Florence A1 La Scola, Bernard A1 Colson, Philippe YR 2024 UL http://medrxiv.org/content/early/2024/12/13/2024.12.11.24318723.abstract AB We report a 19-fold increase in 2024 of qPCR diagnoses of Chlamydia pneumoniae infections in Marseille, Southern France, with 37 cases versus 10 between 2018-2023. These mostly affected children, and young adults. We obtained four C. pneumoniae genomes, all of serotype ST16, suggesting an epidemic circulation in our geographical area.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the French Government under the Investments for the Future programme managed by the National Agency for Research (ANR), Mediterranee Infection 10-IAHU-03 and by the French Ministry of Higher Education, Research and Innovation and the French Ministry of Solidarity and Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The present study involves data that have been registered on the Health Data Access Portal of Marseille university and public hospitals (Assistance Publique-Hopitaux de Marseille (AP-HM)) under No. PADS24-337, and was approved by the AP-HM Ethics and Scientific Committee.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesChlamydia pneumoniae genomes in one scaffold analyzed here have been submitted to the GenBank sequence database (https://www.ncbi.nlm.nih.gov/genbank/) (11) (GenBank Accession no: CP172581 and CP173416).